

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Mometinib for treating disease-related splenomegaly  
or symptoms in adults with myelofibrosis [ID6141]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Final draft guidance**

(when no draft guidance was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?
<p>During scoping consultation, one stakeholder commented that age over 65 years old is a prognostic factor for myelofibrosis and so, there is potential for clinical efficacy and cost effectiveness to vary for populations over and under 65 years.</p> <p>The committee considered that age over 65 is a prognostic characteristic for myelofibrosis. Age is a protected characteristic under the Equality Act 2010. But because its recommendation does not restrict access to treatment for some people over others, the committee agreed that there were no equality issues relevant to the recommendations.</p>
2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes in section 3.14 of the final draft guidance

**Approved by Associate Director (name):** Ross Dent

**Date:** 24/01/2024